TITLE

Pioneering research on the causes of an MS attack: The 2006 John Dystel Prize for Multiple Sclerosis Research for Dr. William A. Sibley

AUTHOR(S)
King, Martha
PUB. DATE
June 2006
SOURCE
Inside MS;Jun/Jul2006, Vol. 24 Issue 3, p22
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article announces the awarding of the 2006 John Dystel Prize for Multiple Sclerosis (MS) Research to William A. Sibley of the Arizona Health Sciences Center. Sibley's study of people with MS and healthy controls showed that a proportion of all new MS attacks were preceded by a cold. His findings led directly to the development of several disease-modifying drugs. Once it was understood that virus infections triggered MS attacks, Sibley quickly proposed that interferon could be used to tamp them down.
ACCESSION #
21201487

 

Related Articles

  • Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. O'Rourke, K. E. T.; Hutchinson, M. // Multiple Sclerosis (13524585);Feb2005, Vol. 11 Issue 1, p46 

    Estimates of the beta-interferon (IFNB) stopping rate in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) vary and have been mainly derived from multicentre studies. This is a retrospective, hospital chart-based study of 394 patients treated by a single...

  • The Dystel prize.  // Inside MS;Summer97, Vol. 15 Issue 2, p10 

    Presents information on the John Jay Dystel Prize for achievement in multiple sclerosis research in the United States. Establishment of the award in 1994; Amount of the award; Administrators; Funding of the award.

  • Henry F. McFarland wins 1998 John Dystel Prize.  // Inside MS;Summer98, Vol. 16 Issue 2, p34 

    Reports that Doctor Henry F. McFarland, an American neuroimmunologist, was awarded the 1998 John Dystel Prize for Multiple Sclerosis Research. Information on McFarland's studies; His achievements. INSET: Untitled (information on the John Dystel Prize).

  • Twin studies and the heritability of MS: a conclusion. Hawkes, C. H.; MacGregor, A. J. // Multiple Sclerosis (13524585);Jun2009, Vol. 15 Issue 6, p661 

    Objective The classical twin study has the potential to evaluate the relative contribution of genes and environment and guide further research strategies, provided the sampling and methods of analysis are correct. We wish to review all the more informative twin studies on multiple sclerosis...

  • Multiple sclerosis patients’ benefit-risk preferences: Serious adverse event risks versus treatment efficacy. Johnson, F. Reed; Van Houtven, George; Özdemir, Semra; Hass, Steve; White, Jeff; Francis, Gordon; Miller, David W.; Phillips, J. Theodore // Journal of Neurology;Apr2009, Vol. 256 Issue 4, p554 

    The aim of this study is to estimate the willingness of multiple sclerosis (MS) patients to accept life-threatening adverse event risks in exchange for improvements in their MS related health outcomes. MS patients completed a survey questionnaire that included a series of choice-format conjoint...

  • Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. Pittas, Fotini; Ponsonby, Anne-Louise; van der Mei, Ingrid A. F.; Taylor, Bruce V.; Blizzard, Leigh; Groom, Patricia; Ukoumunne, Obioha C.; Dwyer, Terry // Journal of Neurology;Apr2009, Vol. 256 Issue 4, p577 

    Multiple sclerosis has a variable disease course. The contribution of modifiable lifestyle factors to disease course has not been well studied, although one cohort has reported that smoking is associated with conversion to secondary progressive MS course and another that smoking is not. We...

  • Medical researchers ID potential new drug target that could stop debilitating effects of MS.  // Biomedical Market Newsletter;10/31/2011, Vol. 21, p383 

    The article reports on the discovery of a potential new drug for multiple sclerosis (MS) by medical researchers at the University of Alberta in Edmonton in 2011. It mentions that the new drug could prevent physical disability related with the disease after the drug is developed. According to...

  • Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. De Stefano, Nicola; Curtin, Fran�ois; Stubinski, Bettina; Blevins, Gregg; Drulovic, Jelena; Issard, Delphine; Shotekov, Penko; Gasperini, Claudio // Multiple Sclerosis (13524585);Jul2010, Vol. 16 Issue 7, p888 

    This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-�1a in relapsing-remitting multiple sclerosis (RRMS). Patients (n=180) were randomized (2 : 1) to IFN-�1a or placebo for 16 weeks; all patients then received IFN-�1a for 24 weeks. Monthly...

  • CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment. Alvarez-Lafuente, Roberto; Blanco-Kelly, Fiona; Garcia-Montojo, Marta; Mart�nez, Alfonso; Heras, Virginia De Las; Dominguez-Mozo, Maria Inmaculada; Bartolome, Manuel; Garcia-Martinez, Angel; Concha, Emilio Gomez De la; Urcelay, Elena; Arroyo, Rafael // Multiple Sclerosis Journal;May2011, Vol. 17 Issue 5, p513 

    Background: In a prior study of our group we found an up-regulation of CD46 expression in a cohort of Spanish multiple sclerosis (MS) patients.Objective: To evaluate the potential role of CD46 in the response to interferon-beta treatment in MS patients through the analysis of five tagging single...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics